Residual paralysis caused by 50 mg rocuronium after reversal with 4 mg/kg sugammadex: a case report.
BMC Anesthesiol
; 21(1): 154, 2021 05 20.
Article
em En
| MEDLINE
| ID: mdl-34016059
ABSTRACT
BACKGROUND:
Rocuronium-induced neuromuscular blockade can be quickly and completely reversed by administration of an optimal dose of sugammadex. Sugammadex antagonizes rocuronium-induced neuromuscular blockade by encapsulating rocuronium. Herein, we report a case of residual neuromuscular paralysis in which the recommended dose of sugammadex (4 mg·kg- 1) failed to antagonize a rocuronium-induced blockade. CASE PRESENTATION A 71-year-old man (body mass index 26.7 kg·m- 2) underwent endoscopic submucosal dissection of early-stage gastric cancer. He had no known factors that may have affected the effects of rocuronium and sugammadex. He received rocuronium (50 mg; 0.7 mg·kg- 1) for anesthesia induction. No additional rocuronium was administered during the 71-min procedure. Ninety-four minutes after rocuronium administration, neuromuscular monitoring showed 20 twitches in response to post-tetanic count stimulation. The train-of-four (TOF) ratio was not measurable despite sugammadex (280 mg; 4 mg/kg) administration, although four weak twitches in response to TOF stimulation appeared in 3 min. The TOF ratio became detectable following administration of an additional dose of sugammadex (120 mg; 1.7 mg·kg- 1), and it recovered to 107% 8 min after the second dose. The patient opened his eyes; moved his neck, arms, and limbs; and regained consciousness. The trachea was extubated and the patient was transferred to the ward.CONCLUSIONS:
Neuromuscular monitoring should be used if a neuromuscular blockage agent is administered, even if the recommended dose of sugammadex is administered.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Paralisia
/
Fármacos Neuromusculares não Despolarizantes
/
Bloqueio Neuromuscular
/
Sugammadex
/
Rocurônio
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
BMC Anesthesiol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Japão